Qiang Zhang, Ph.D.

Senior Principal Scientist @ Johnson & Johnson Innovative Medicine

About

A results-oriented and value-driven medicinal chemist with over 20 years of experience in multidisciplinary drug discovery and development, including 19+ years in the pharmaceutical industry. Proven expertise in drug discovery and early development, contributing to the advancement of multiple drug candidates into clinical trials. Played a key role in advancing Lumateperone (CAPLYTA®) from early discovery through to commercial launch. Inventor of several novel molecules currently in clinical trials, including key contributions to psychedelic drug programs. Demonstrated proficiency in project management, supervision of scientists, and collaboration with CROs/CMOs. Published 27+ peer-reviewed articles and holds 26+ patents and patent applications.

Country

United States

City

New York City Metropolitan Area

Industry

Pharmaceuticals

Skill

Drug Discovery, Commercialization, Cancer, HPLC, Chemistry, NMR, Polymers, Organic Chemistry, Clinical Trials

Experience

Senior Principal Scientist

Johnson & Johnson Innovative Medicine

2026-1 - Present · 9 mos

United States

Senior Principal Scientist

Intra-Cellular Therapies

2024-1 - 2025-12 · 2 yrs

New York, United States

Principal Scientist

Intra-Cellular Therapies

2019-1 - 2023-12 · 5 yrs

Senior Scientist II

Intra-Cellular Therapies

2017-1 - 2018-12 · 2 yrs

Greater New York City Area

Senior Scientist I

Intra-Cellular Therapies

2005-9 - 2016-12 · 11 yrs 4 mos

Greater New York City Area

Acting as a leading and major contributor for several drug discovery and development programs, especially for Central Nervous System (CNS) disease and oncology. Hands-on experience from early discovery to late development. Extensive knowledge for current drug design and synthesis, drug pharmacokinetics, receptor pharmacology and chemical process development etc..

Research and Teaching Specialist

Robert Wood Johnson Medical School- Rutgers University

2002 - 2005 · 3 yrs

New Jersey

Designed and synthesized small molecules for cancer, pain management and cardiovascular diseases. The novel delta Opioid lead compound for pain management was successfully licensed out to a big pharma.